Parameter
| Biomarker | CD8+T cell | Full name | Cluster of differentiation8+T cell | Molecular Type | Immunological cell |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction of treatment response and prognosis | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Blood (flow cytometry) | ||
| Pathobiological Mechanisms | Baseline level association of complete response with survival in relapsed/refractory patients. | ||||
| Clinical Availability Status | Research validation phase: Validation of 78 R2-GDP protocol patients, requiring multi-protocol validation and standardized testing. | ||||
| Notes and Dynamics | Exploring the correlation between immune checkpoint inhibitors and therapeutic efficacy, standardizing flow cytometry detection strategies. | ||||